{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:37:32Z","timestamp":1791067052112,"version":"4.1.0"},"reference-count":54,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epileptic Disorders"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Antiseizure medications (ASMs) can induce the activity of drug\u2010metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P\u2010glycoprotein (P\u2010gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P\u2010gp substrates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This systematic review and network meta\u2010analysis (NMA) was registered in PROSPERO (CRD42023473609) and performed following PRISMA 2020 guidelines. MEDLINE, EMBASE, and Cochrane Library were searched until October 22, 2025, with additional searches conducted in the FDA and EMA databases and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrial.gov\">ClinicalTrial.gov<\/jats:ext-link>\n                      . Studies were included if they were prospective and the ASM was used as monotherapy for \u22655\u2009days. The primary endpoint was the substrate area under the curve ratio (AUCR) with\/without the ASM. Treatments were ranked by P\u2010scores (range 0\u20131, higher values reflect stronger induction). The point estimate for indirect pairwise comparisons was the standardized mean difference (SMD). Bias risk was assessed using the PKclin tool.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve and six interventional pharmacokinetic studies with 227 and 97 participants were included in the CYP2C9 and P\u2010gp NMAs, respectively. The ASM with the greatest CYP2C9 induction potential was carbamazepine (600\u2009mg\/day, P\u2010score .78). The only statistically significant effect size estimate for CYP2C9 was obtained in the comparison between carbamazepine 600\u2009mg\/day and cenobamate 200\u2009mg\/day (SMD \u2212.42; CI \u2212.76, \u2212.09). Carbamazepine (300 or 600\u2009mg\/day) was also the strongest P\u2010gp inducer (P\u2010scores, .79 and .55, respectively). The effects of its two doses did not differ, and 300\u2009mg\/day had a stronger effect on P\u2010gp compared with the other ASMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>Despite variability in populations, substrate drugs, and doses, our findings demonstrate that carbamazepine is an inducer at 300\u2009mg\/day, and that ASMs can rank differently as CYP2C9 versus P\u2010gp inducers. Therefore, the safety of ASM polytherapy cannot be extrapolated from one pathway to another for treatment selection, for example, for post\u2010stroke epilepsy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/epd2.70232","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:11:47Z","timestamp":1775639507000},"page":"855-867","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Induction of cytochrome P450 2C9 and P\u2010glycoprotein activity by antiseizure medications: A systematic review and network meta\u2010analysis"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0461-4272","authenticated-orcid":false,"given":"Hagar","family":"Cohen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine The Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6713-1010","authenticated-orcid":false,"given":"Nahawand","family":"Bahash","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine The Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-566X","authenticated-orcid":false,"given":"Tomer","family":"Ben\u2010Shushan","sequence":"additional","affiliation":[{"name":"Medical Library Authority The Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1559-9258","authenticated-orcid":false,"given":"Ilan","family":"Matok","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine The Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-3532","authenticated-orcid":false,"given":"Sara","family":"Eyal","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine The Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000341789.77291.8d"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02529.x"},{"key":"e_1_2_12_4_1","unstructured":"FDA U.S. Food & Drug Administration.Drug approvals and databases.2026. [cited 2026 Jan 9]. Available from:https:\/\/www.fda.gov\/drugs\/development\u2010approval\u2010process\u2010drugs\/drug\u2010approvals\u2010and\u2010databases"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1072"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2605"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18144"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8010001"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2333"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.668"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2008"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.03.017"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17822"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.67"},{"key":"e_1_2_12_15_1","unstructured":"FDA.For Healthcare Professionals | FDA's Examples of Drugs that Interact with CYP Enzymes and Transporter Systems. Updated June 27 2025 [cited 2025 Sept 30]. Available from:https:\/\/www.fda.gov\/drugs\/drug\u2010interactions\u2010labeling\/healthcare\u2010professionals\u2010fdas\u2010examples\u2010drugs\u2010interact\u2010cyp\u2010enzymes\u2010and\u2010transporter\u2010systems"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00829.x"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199912000-00004"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1916"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2670"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_12_21_1","volume-title":"Cochrane Handbook for systematic reviews of interventions version 6.3 (updated Feb 2022)","author":"Higgins JPT","year":"2022"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_2_12_23_1","unstructured":"European Medicines Agency (EMA). [cited 2025 Oct 29]. Available from:https:\/\/www.ema.europa.eu\/en."},{"key":"e_1_2_12_24_1","volume-title":"Antiepileptic drug interactions: a clinical guide","author":"Patsalos P","year":"2022"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0236-8"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1542063"},{"key":"e_1_2_12_29_1","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.5 (updated August 2024)","author":"Higgins JPT","year":"2024"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03519.x"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1213"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00867-1"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.054866"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.2012.01028.x"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00293-5"},{"key":"e_1_2_12_36_1","unstructured":"FDA.M12 Drug Interaction Studies. Guidance for Industry. Updated Aug 2024. [cited 2026 Feb 14]. Available from:https:\/\/www.fda.gov\/media\/161199\/download"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13357"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1515\/DMDI.2003.19.4.287"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-025-01514-3"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/87912"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.087072"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.62.3.737"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18584"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2018.03.023"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3460"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.70083"},{"key":"e_1_2_12_47_1","unstructured":"OpenPrescribing.OpenPrescribing.net Bennett Institute for Applied Data Science University of Oxford. Digoxin (0201010F0). Part of chapter\u00a02 Cardiovascular System section\u00a02.1 Positive inotropic drugs paragraph 2.1.1 Cardiac glycosides.2025. [cited 2025 Nov 14]. Available from:https:\/\/openprescribing.net\/chemical\/0201010F0\/"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0096-2"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197603252941305"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00795-z"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00547368"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01740672"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100226"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.382"}],"container-title":["Epileptic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epd2.70232","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/epd2.70232","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epd2.70232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:53:00Z","timestamp":1781772780000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epd2.70232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/epd2.70232"],"URL":"https:\/\/doi.org\/10.1002\/epd2.70232","archive":["Portico"],"relation":{},"ISSN":["1294-9361","1950-6945"],"issn-type":[{"value":"1294-9361","type":"print"},{"value":"1950-6945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"2025-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}